What was the main driver of Boston Scientific's revenue growth in Q1 2004?

The primary driver of revenue growth was the recent US launch of the TAXUS Express2 paclitaxel-eluting coronary stent system. This new technology contributed significantly to both US and international sales figures, especially as physicians continue to shift from bare metal stents to drug-eluting stent technology.

How is Boston Scientific managing its debt and liquidity?

Boston Scientific had $946 million in commercial paper outstanding and utilized its revolving credit facilities totaling $1,265 million. The company plans to refinance its existing revolving credit facilities to $2,000 million in Q2 2004 to support strategic growth objectives and maintain borrowing flexibility. They also have senior notes of $500 million maturing in March 2005, classified as a current liability.

What are the key risks and uncertainties facing Boston Scientific, particularly concerning the TAXUS stent?

Key risks include the competitive landscape in the drug-eluting stent market, potential challenges in manufacturing and maintaining adequate inventory levels for the TAXUS stent, the rate of physician adoption and reimbursement policies, potential new competitive launches, and the outcome of ongoing patent litigation. The company is also reviewing reports of balloon withdrawal difficulty during TAXUS angioplasty procedures.

How did the company's operating segments perform?

The United States segment saw a 20% increase in revenue, largely due to the TAXUS stent. International markets collectively grew by 54%, with Europe up 62% and Inter-Continental up 104% (constant currency: Europe 41%, Inter-Continental 79%). The Cardiovascular Group was the largest segment, showing 44% growth, driven by stent sales.

BSX 10-Q Quarterly Report Q1 FY2004 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation's (BSX) first quarter of 2004 demonstrated robust growth, with net sales increasing by 34% to $1.082 billion, driven significantly by the recent US launch of the TAXUS drug-eluting stent. This substantial revenue growth, coupled with improved gross margins, led to a doubling of net income to $194 million, or $0.23 per diluted share, compared to the prior year. The company's strategic focus on interventional cardiology, particularly its drug-eluting stent technology, positions it for continued expansion, although it faces intense competition and ongoing litigation in this dynamic market.

Key Highlights

1Net sales surged by 34% to $1.082 billion in Q1 2004, a significant increase from $807 million in Q1 2003.
2Net income more than doubled to $194 million ($0.23/share diluted) from $97 million ($0.11/share diluted) year-over-year.
3The TAXUS Express2 paclitaxel-eluting coronary stent system, recently launched in the US, was a primary driver of revenue growth, contributing $98 million in US sales.
4International revenues showed strong growth of 54% to $506 million, bolstered by the TAXUS stent sales in Europe and Inter-Continental markets.
5Gross profit margin improved to 73.0% from 72.0%, despite an inventory charge related to TAXUS stent shelf-life.
6The company is actively managing its debt and credit facilities, planning to refinance existing revolving credit facilities to up to $2,000 million.
7Boston Scientific faces significant ongoing patent litigation with competitors like Johnson & Johnson, Medtronic, and Medinol, which could impact future operations.

BOSTON SCIENTIFIC CORP Quarterly Report for Q1 Ended Mar 31, 2004

Summary

Key Highlights

Frequently Asked Questions